lenvatinib and pembrolizumab melanoma

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
lenvatinib and pembrolizumab melanoma	1.6	1	4438	95	37
lenvatinib	1.06	0.3	1172	10	10
and	1.67	0.3	3455	10	3
pembrolizumab	1.83	0.7	9116	58	13
melanoma	0.99	0.9	4123	35	8

Keyword	CPC	PCC	Volume	Score
lenvatinib and pembrolizumab melanoma	0.77	0.3	8180	60
pembrolizumab lenvatinib melanoma	1.84	0.2	7411	43
nivolumab and pembrolizumab for melanoma	0.8	0.1	460	54
lenvatinib pembrolizumab colorectal cancer	1.88	0.6	5577	23
pembrolizumab and lenvatinib macmillan	0.45	0.3	7290	50
lenvatinib + pembrolizumab	0.63	0.3	3191	65
lenvatinib pembrolizumab clinical trials	0.31	0.7	3754	15
lenvatinib in combination with pembrolizumab	1.85	0.1	5755	83
lenvatinib pembrolizumab renal cell carcinoma	0.05	0.5	4372	24
lenvatinib pembrolizumab kidney cancer	0.7	0.5	9865	34
pembrolizumab versus nivolumab for melanoma	1.7	0.8	4283	8
lenvatinib pembrolizumab endometrial cancer	0.87	0.2	6025	54
neoadjuvant pembrolizumab in melanoma	0.88	0.3	4783	53
pembrolizumab in metastatic melanoma	0.95	0.2	9619	24
pembrolizumab vs nivolumab melanoma	1.32	0.3	4741	36
lenvatinib and pembrolizumab rcc	0.44	0.7	8080	72
pembrolizumab lenvatinib uterine cancer	1.39	0.4	1961	86
pembrolizumab adjuvant melanoma nejm	1.92	0.3	6090	94
lenvatinib pembrolizumab fda approval	0.75	0.5	6539	28
nejm neoadjuvant pembrolizumab melanoma	1.91	0.2	6218	93